Enjoy complimentary customisation on priority with our Enterprise License!
The chronic obstructive pulmonary disease drugs market size is forecast to increase by USD 7.19 billion at a CAGR of 6.24% between 2023 and 2028. The Chronic Obstructive Pulmonary Disease (COPD) drugs market is experiencing significant growth due to several factors. The primary driver is the rising prevalence of COPD, which is largely attributed to tobacco smoke and exposure to chemicals. Asthma and genetic factors, such as alpha-1-antitrypsin deficiency, also contribute to the disease. However, despite the increasing number of cases, diagnosis rates for COPD remain low. This creates an opportunity for market expansion. Another trend in the market is the growing research in curative approaches for COPD, which could potentially lead to more effective treatments and improved patient outcomes. Lifestyle changes, such as smoking cessation and reducing alcohol consumption, can also help manage COPD symptoms and reduce the need for medications.
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Product
7 Market Segmentation by Distribution Channel
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.